[Newsmp] Two items of eye drops containing rebamipide will be listed on the benefits list next month.
Telmican-Q and Rozetelpine, four-drug combination treatments for hypertension and dyslipidemia, will expand their lineup, and the owner of the anticancer drug Taxol will transfer.
Among the existing products, Ranibizumab (original product name: Lucentis, Novartis) biosimilar Ameliebou will receive a significant cut in the upper limit of benefits.
The Ministry of Health and Welfare revised and issued a revision of the ‘Pharmaceutical benefit list and the table of the upper limit of benefits’ on February 22.
According to the notice, from the 1st of next month (March), two items of rebamipide eye drops, including Samil Pharmaceutical’s Reva-K Eye Drops and Kukje Pharma's Reba-eye Eye Drops 2%, will be newly listed on the benefits list. The upper limit is set at KRW 3,464 per 5ml/bottle.
Additional 40/20/10/5mg and 80/20/10/5 mg of telmisartan, amlodipine, rosuvastatin, ezetimibe four-drug combination Telmican-Q (Jeil Pharmaceutical) and Rozetelpine (Green Cross) will be added.
The maximum amount was set at KRW 2,138 for 40/20/10/5mg and KRW 2,285 for 80/20/10/5mg.
For the anticancer drug Taxol, which Boryung Pharmaceutical took over the copyright from BMS Korea, only the seller has changed, and the existing upper limit of KRW 78,695 per 5ml vial is maintained.
Ameliebou Inj. 10mg/mL’s upper limit will be reduced by 24.5% from 0.23mL/vial KRW 463,773 to KRW 350,000.
The upper limit of Lenaldo Cap. 5 and 10mg (lenalidomide) of Kwang Dong Pharmaceutical will fall by 21% from KRW 71,792 and 76,690 to KRW 56,600 and 60,500.
Yungjin Pharm.’s Yungjin Fluoxetine Cap. 10 and 20mg will be lowered by 38.4% and 53.4% from KRW 292 and 483 to KRW 180 and 225.
Alovogen Korea’s Libolone Tab. 2.5mg will also be cut by 14.8% from KRW 223 to KRW 190.
AbbVie Korea’s Skyrizi Prefilled Syringe Inj., which expands its indication to psoriatic arthritis, is expected to be reduced by 6.1% from KRW 1,247,627 per 0.83mL/tube to KRW 1,171,500.
Moreover, the upper limit of Amgen Korea’s PCK9 inhibitor Repatha Inj. Prefilled Pen will also be cut by 3.7% from KRW 125,701 to KRW 121,000.
